Announcement
Concepta PLC : myLotus? successful UK launch
RNS Number : 6039K
Concepta PLC
17 December 2018
17 December 2018
Concepta Plc
("Concepta" or the "Company")
myLotus® successful UK launch
Concepta Plc (AIM: CPT), the innovative UK healthcare company and developer of the proprietary self-test platform ("myLotus®") and suite of emerging test products targeting the mobile health market is pleased to advise on the successful launch in the UK of its breakthrough myLotus® product for women's fertility.
myLotus® allows women to self-test to identify their optimal fertile days thereby improving their chances of naturally getting pregnant. myLotus® enables women to monitor their fertile phase as part of their menstrual cycle and is the only home test to 'quantitatively' measure personalised hormone levels and the 'rate-of-change' of these levels preceding ovulation to help aid a natural conception. Users measure, record and track their hormone levels and follow their fertility journey in an accompanying free downloadable app.
Whilst awareness, profile and sales of the myLotus® device are just commencing, feedback from early users and fertility bloggers has been very positive can be viewed online at www.myLotus.com
Discussions have also commenced with 'Key Opinion Leaders' to advise on the wider use of myLotus® especially for women who wish to carefully monitor their hormonal levels and for those who have previously struggled to conceive naturally, enabling an alternative for couples prior to considering more costly IVF treatment.
In addition to the growing myLotus® digital UK presence, the Company is preparing plans for the roll-out of myLotus® across Europe under its CE-mark approval. Commercial discussions have also commenced with retail providers to make myLotus® more broadly available across the UK.
Matthew Walls, Chairman said: "Although marketing and communications around myLotus® are just beginning, feedback from the early users has been exceptional. We will be raising awareness of the value of the myLotus® device and its window on fertility over the coming months via an increased online presence, Key Opinion Leaders and marketing of our initial fertility case studies. Further details can be viewed at www.myLotus.com."
Enquiries
Company: www.conceptaplc.com, Product: www.myLotus.com
Matthew Walls, Chairman
Tel: +44 (0) 1234 866601
SPARK Advisory Partners Limited (Nomad)
Neil Baldwin / Mark Brady
Tel: +44 (0)20 368 3550
Novum Securities
Colin Rowbury
+44 (0) 20 7399 9400
Yellow Jersey PR Limited (Financial PR)
Felicity Winkles Tel: +44 (0) 774 884 3871
About Concepta Plc:
Concepta Plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus®, targeted at the personalised mobile health market with a primary focus on increasing a woman's chances of getting pregnant naturally and for unexplained infertility in women.
myLotus® is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus® is to help women conceive naturally by identifying their window of fertility and optimal time for conception.
The Company has received CE-mark certification for myLotus® and has launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2019.
myLotus® is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of consumers won't typically be offered medical intervention until 12 months of unsuccessfully trying, with IVF typically not offered until two years. Research indicates couples start to take positive action ahead of this time with little medical support to help them do so.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
PRLUNUKRWOAUAAA
;